Musaberk Goksel, MD
Hematology & Oncology · Soldotna, AKNPI 1174576490
Payments from drug & device makers
Across 192 payments — averaging $2631.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$254K
- Eisai Inc.$149K
- Boehringer Ingelheim$40K
- Daiichi Sankyo Inc.$19K
- United Therapeutics Corporation$18K
- Seagen Inc.$14K
- plus $11K from 33 others
What the payments were for
- Food & beverage$1,88673%
- Education$69327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 42 | $253,953 |
| Eisai Inc. | 52 | $149,140 |
| Boehringer Ingelheim | 1 | $40,039 |
| Daiichi Sankyo Inc. | 12 | $19,090 |
| United Therapeutics Corporation | 3 | $18,472 |
| Seagen Inc. | 3 | $14,041 |
| Novartis | 4 | $8,222 |
| Astellas Pharma US Inc | 12 | $436 |
| AbbVie(2 entities) | 5 | $341 |
| Johnson & Johnson | 7 | $166 |
| EMD Serono, Inc. | 3 | $162 |
| AstraZeneca | 4 | $125 |
| Genmab U.S., Inc. | 1 | $125 |
| Tempus AI, Inc | 3 | $83 |
| Genentech USA, Inc. | 4 | $80 |
| Bristol Myers Squibb | 3 | $79 |
| Bayer | 4 | $65 |
| Novocure Inc. | 1 | $53 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 1 | $49 |
| Sanofi | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| Tolmar Pharmaceuticals, Inc. | 2 | $41 |
| Exelixis Inc. | 2 | $36 |
| Gilead | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Adaptive Biotechnologies Corporation | 1 | $26 |
| GSK | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Pfizer | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPKINLY$125
How this compares
Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 43 | $1,536 |
| Hydroxyurea | 20 | $349 |
| Letrozole | 14 | $253 |
| Prednisone | 24 | $177 |
| Ondansetron OdtOndansetron | 11 | $132 |
| Acyclovir | 14 | $100 |
| Levothyroxine Sodium | 19 | $98 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Soldotna
- David EilenderSoldotna$19K
- Steven LiuAnchorage$6.9M
- Theodore KimAnchorage$1.4M
- Max RabinowitzAnchorage$14K
- Mary KlixAnchorage$13K
- Mary StewartAnchorage$9K
- Kendal WebbAnchorage$8K
- Natalie WallaceAnchorage$8K
- Shannon SmileyAnchorage$6K
- Charles BuessAnchorage$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.